225 related articles for article (PubMed ID: 22475245)
1. The effect of tumor necrosis factor-α antagonists on arterial stiffness in rheumatoid arthritis: a literature review.
Dulai R; Perry M; Twycross-Lewis R; Morrissey D; Atzeni F; Greenwald S
Semin Arthritis Rheum; 2012 Aug; 42(1):1-8. PubMed ID: 22475245
[TBL] [Abstract][Full Text] [Related]
2. Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis.
Van Doornum S; McColl G; Wicks IP
Rheumatology (Oxford); 2005 Nov; 44(11):1428-32. PubMed ID: 16076882
[TBL] [Abstract][Full Text] [Related]
3. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy.
Mäki-Petäjä KM; Hall FC; Booth AD; Wallace SM; Yasmin ; Bearcroft PW; Harish S; Furlong A; McEniery CM; Brown J; Wilkinson IB
Circulation; 2006 Sep; 114(11):1185-92. PubMed ID: 16952987
[TBL] [Abstract][Full Text] [Related]
4. The effect of TNF-a antagonists on aortic stiffness and wave reflections: a meta-analysis.
Vlachopoulos C; Gravos A; Georgiopoulos G; Terentes-Printzios D; Ioakeimidis N; Vassilopoulos D; Stamatelopoulos K; Tousoulis D
Clin Rheumatol; 2018 Feb; 37(2):515-526. PubMed ID: 28484887
[TBL] [Abstract][Full Text] [Related]
5. No significant changes in arterial stiffness in patients with ankylosing spondylitis after tumour necrosis factor alpha blockade treatment for 6 and 12 months.
Mathieu S; Pereira B; Couderc M; Rabois E; Dubost JJ; Soubrier M
Rheumatology (Oxford); 2013 Jan; 52(1):204-9. PubMed ID: 23065359
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study.
Angel K; Provan SA; Gulseth HL; Mowinckel P; Kvien TK; Atar D
Hypertension; 2010 Feb; 55(2):333-8. PubMed ID: 20038753
[TBL] [Abstract][Full Text] [Related]
7. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
[TBL] [Abstract][Full Text] [Related]
8. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists.
Isaacs JD
Expert Opin Biol Ther; 2009 Dec; 9(12):1463-75. PubMed ID: 19916731
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.
Bombardieri S; Ruiz AA; Fardellone P; Geusens P; McKenna F; Unnebrink K; Oezer U; Kary S; Kupper H; Burmester GR;
Rheumatology (Oxford); 2007 Jul; 46(7):1191-9. PubMed ID: 17504821
[TBL] [Abstract][Full Text] [Related]
11. Etanercept normalises left ventricular mass in patients with rheumatoid arthritis.
Daïen CI; Fesler P; du Cailar G; Daïen V; Mura T; Dupuy AM; Cristol JP; Ribstein J; Combe B; Morel J
Ann Rheum Dis; 2013 Jun; 72(6):881-7. PubMed ID: 22872022
[TBL] [Abstract][Full Text] [Related]
12. Effects of biologics on vascular function and atherosclerosis associated with rheumatoid arthritis.
Kerekes G; Soltész P; Dér H; Veres K; Szabó Z; Végvári A; Shoenfeld Y; Szekanecz Z
Ann N Y Acad Sci; 2009 Sep; 1173():814-21. PubMed ID: 19758233
[TBL] [Abstract][Full Text] [Related]
13. [TNF antagonists in therapy of rheumatoid arthritis].
Oberpichler-Schwenk H
Med Monatsschr Pharm; 1999 Nov; 22(11):334-9. PubMed ID: 10596266
[No Abstract] [Full Text] [Related]
14. Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis?
Tam LS; Kitas GD; González-Gay MA
Rheumatology (Oxford); 2014 Jun; 53(6):1108-19. PubMed ID: 24501245
[TBL] [Abstract][Full Text] [Related]
15. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.
Mancarella L; Bobbio-Pallavicini F; Ceccarelli F; Falappone PC; Ferrante A; Malesci D; Massara A; Nacci F; Secchi ME; Manganelli S; Salaffi F; Bambara ML; Bombardieri S; Cutolo M; Ferri C; Galeazzi M; Gerli R; Giacomelli R; Grassi W; Lapadula G; Cerinic MM; Montecucco C; Trotta F; Triolo G; Valentini G; Valesini G; Ferraccioli GF;
J Rheumatol; 2007 Aug; 34(8):1670-3. PubMed ID: 17611987
[TBL] [Abstract][Full Text] [Related]
16. TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma.
Sarzi-Puttini P; Atzeni F; Shoenfeld Y; Ferraccioli G
Autoimmun Rev; 2005 Mar; 4(3):153-61. PubMed ID: 15823501
[TBL] [Abstract][Full Text] [Related]
17. Differentiating the efficacy of tumor necrosis factor inhibitors.
Haraoui B
J Rheumatol Suppl; 2005 Mar; 74():3-7. PubMed ID: 15742457
[TBL] [Abstract][Full Text] [Related]
18. Infliximab improves vascular stiffness in patients with rheumatoid arthritis.
Wong M; Oakley SP; Young L; Jiang BY; Wierzbicki A; Panayi G; Chowienczyk P; Kirkham B
Ann Rheum Dis; 2009 Aug; 68(8):1277-84. PubMed ID: 18930987
[TBL] [Abstract][Full Text] [Related]
19. Clinical improvement in rheumatoid arthritis is associated with healthier microvascular function in patients who respond to antirheumatic therapy.
Galarraga B; Belch JJ; Pullar T; Ogston S; Khan F
J Rheumatol; 2010 Mar; 37(3):521-8. PubMed ID: 20080919
[TBL] [Abstract][Full Text] [Related]
20. Etanercept improves inflammation-associated arterial stiffness in rheumatoid arthritis.
Galarraga B; Khan F; Kumar P; Pullar T; Belch JJ
Rheumatology (Oxford); 2009 Nov; 48(11):1418-23. PubMed ID: 19734293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
